drugset / Trial / NCT04549428
Atezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced Oligoprogressive NSCLC
Phase 2
Terminated
12 enrolled
Oncology Institute of Southern Switzerland
Clinical Trial Unit Ente Ospedaliero Cantonale · collabEnte Ospedaliero Cantonale, Bellinzona · collabIstituto Cantonale di Patologia · collab
NaSingle-groupOpen-labelTreatment
Summary
Multicentre, phase II, open-label, single-arm study evaluating the preliminary efficacy, safety and tolerability of atezolizumab in association with palliative radiotherapy in adult patients diagnosed with advanced (stage IV) NSCLC, irrespective of PD-L1 status, and who have oligoprogressed to both immunotherapy with an anti PD-1 agent (e.g., pembrolizumab or nivolumab) and 1 line of chemotherapy.
Timeline
- Start
- 2020-10-01
- Primary completion
- 2023-01-23
- Completion
- 2025-05-31
Outcome
Outcome not reported
Stopped: “Terminated for futility, as determined by an interim data analysis.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | 1200 mg | Intravenous |